Reduced-intensity conditioning (RIC) has offered many primary immunodeficiency disorder (PID) patients who are ineligible for myeloablative regimens a chance of cure. However, the beneficial role of RIC was questioned following reports suggesting higher chance of rejection and lower symptom resolution rate in mixed chimerism settings. Forty-five children affected by PIDs with a median age of 21 months underwent allogeneic hematopoietic stem cell transplantation in our institute from 2007 to 2013. All patients received an identical RIC regimen. Forty-one patients had successful primary engraftment (91%). Of the successful engraftments, 80% (n = 33) had stable full donor chimerism at last contact. Overall, eleven transplant-related mortalities were reported including five patients due to sepsis, three children due to grade IV acute GvHD, two due to chronic GvHD and one patient due to sepsis after primary graft failure. The median post-transplantation follow-up of deceased patients was 55 days. Five-year overall survival and disease-free survival was 75.6% and 68.89%, respectively. All surviving patients with successful engraftment became disease free, regardless of having full or mixed chimerism. Our study suggests that RIC regimen provides satisfactory rates of successful engraftment and full chimerism. Furthermore, patients with mixed chimerism were stable in long-term follow-up and this chimerism status offered the potential to resolve symptoms of immunodeficiency.
INTRODUCTION
Primary immunodeficiency disorders (PIDs) are a group of rare defects characterized by an intrinsic dysfunction in innate and/or adaptive immune systems. 1 These defects in the human immune system may lead to severe complications, such as recurrent and resistant infections. [2] [3] [4] In some PIDs, patients survive for a long time with the aid of intravenous immunoglobulin replacement therapy and antibiotic prophylactic regimens. However, certain types of PIDs are fatal and without curative therapy, death will ensue in infancy and childhood period. [5] [6] [7] Allogeneic hematopoietic stem cell transplantation (HSCT), one of the current promising treatments, has raised hopes of cure for the indicated patients. 8 For years, myeloablative conditioning (MAC) regimen was the only known preparative regimen for HSCT. 9 However, application of MAC in PID patients with pre-existing comorbidities including resistant infections is challenged by the increased mortality associated with it. [10] [11] [12] In the 1990s, reduced-intensity conditioning (RIC) regimen was presented as an alternative preparative regimen aiming to obtain a reliable engraftment with lower rates of organ toxicity. [13] [14] [15] This strategy has the advantage of extending HSCT to patients ineligible for MAC due to comorbidities such as infections and organ dysfunctions. Nevertheless, concerns over RIC's ability to achieve and maintain engraftment have emerged, considering evidence pointing to higher incidence of engraftment failure following RIC-HSCTs. 16, 17 Moreover, mixed chimerism, a common state following RIC-HSCTs, has been under scrutiny for ambiguity surrounding its power to resolve symptoms of the underlying disease. 10, 13, 18 More than four decades have passed since the first reports of successful HSCT in PID patients. 19, 20 Nevertheless, as PIDs are rare and a large enough sample of patients who have undergone the same RIC protocol in the same setting is not accessible, the optimal RIC protocol for PIDs remains to be established.
Our pediatric transplant unit was founded in the hematologyoncology and stem cell transplantation research center (HORCSCT) in 2007. Considering a history of recurrent infections in the setting of PID due to late referral of patients and the national bacille Calmette-Guérin (BCG) vaccination policy leading to a high rate of disseminated BCG infection (BCG-osis) in PID patients in our country, the Institutional Review Board of HORCSCT has approved an identical RIC protocol based on fludarabine for all PID patients since establishment of its pediatric transplant unit. This scientific environment provided us with an opportunity to analyze this particular regimen in these rare disorders and to determine the factors associated with best outcomes. We also sought to investigate mixed chimerism and its modifying effect on the disease course.
MATERIALS AND METHODS

Patients' characteristics
A prospective study of pediatric patients affected by PID who had undergone HSCT in HORCSCT between February 2007 and February 2013 was performed. Patients' initial diagnosis was made at referral centers and was confirmed at Immunology, Asthma and Allergy Research Institute. All children in need of HSCT entered this study.
An HLA-identical sibling was the optimal donor. However, in cases of consanguineous marriages and no potential HLA-compatible sibling donor other members of the extended family underwent HLA typing. When no full-match donor among family members was available, alternative options such as unrelated, cord blood (CB) and haplo-identical donors were considered. HLA-A, -B and -DRB1 were assessed by low-resolution molecular typing in sibling pairs. High-resolution typing of HLA-A, B, C and DRB1 was employed in non-sibling pairs.
Conditioning regimen and GvHD prophylaxis
According to the HORCSCT guidelines, informed written consent was obtained from parents before the transplantation procedure. All patients received the same RIC protocol before HSCT. Children were conditioned with fludarabine 30 mg/m 2 /day for 5 days (days − 8 to − 4) followed by horse antithymocyte globulin (ATGAM, Pfizer Inc., New York, NY, USA) 10 mg/kg/day (days − 4 to − 1) and melphalan 70 mg/m 2 /day (days − 3 and − 2). HORCSCT's review board and ethics committee approved the mentioned RIC protocol.
GvHD prophylaxis regimen was composed of cyclosporine A, starting with 1.5 mg/kg/day on day − 1 and later changing to 3mg/kg/day on day +7 in PBSC setting and on day +11 for bone marrow (BM) and umbilical CB collections, and methyl prednisolone from day − 5 with 1 mg/kg/day (days − 5 to +7) that was altered to 0.5 mg/kg/day from day +8 to day +14. Cyclosporine A level (therapeutic range: 100-250 ng/ml) was monitored twice weekly.
Stem cell collection
Stem cell sources consisted of BM, PBSCs and umbilical CB. Before collection of PBSCs, donors received G-CSF 5 μg/kg/day for 3 consecutive days (days − 4 to − 2) and a 10-μg/kg dose of G-CSF on day − 1. On the day of transplantation, PBSCs were collected through continuous-flow leukapheresis. BM stem cells were harvested by aspiration of donors' bilateral iliac crest's marrow cavities on the day of transplantation.
Supportive measures
Supportive measures were identical for the entire group of patients as they were cared for in single isolated rooms equipped with HEPA filters.
Antimicrobial prophylaxis included acyclovir 750-1500 mg/m 2 /day intravenously (days − 10 to − 1) and 1200-2400 mg/m 2 /day orally (from the day of transplantation up to 2 months after cessation of all immunosuppressive medications) to preclude herpes simplex and varicella zoster infections. Trimethoprim-sulfamethoxazole 5mg/kg/day (days − 10 to − 1 and days +36 to +2 years) and itraconazole 5 mg/kg/day (commenced on day − 11 and continued for at least 3 months) were also administered to prevent Pneumocystis jiroveci and fungal infections, respectively. Neutropenic fever was treated with broad-spectrum intravenous antibiotics. CMV infection was monitored via quantitative CMV-DNA PCR or CMV PP65 antigen assay, twice weekly. Positive CMV tests were treated with gancyclovir 5 mg/kg twice daily for 14 days and 5 mg/kg/day for the next 7 days or until the test became negative. All patients received irradiated blood products if needed.
A single dose of intravenous immunoglobulin 0.5 g/kg was given on day − 9 to all patients. It was recommenced on day +7 with 0.5 g/kg and was administered every 21 days afterwards for the first year post-transplantation. From day +8, G-CSF 5 μg/kg was employed until an ANC of 1 × 10 9 /L or more was detected.
Clinical and laboratory follow-up Patients were followed up weekly for the first month after discharge and every 2 weeks after then, until day +100, and individually thereafter. During each visit, adverse events, infections and GvHD signs and symptoms were investigated.
Chimerism was evaluated through BM aspiration on days +15 and +30 and peripheral blood samples on days +60, +90, +180, +365 and thenceforth every 6 months by employing genomic DNA PCR for amplification of STRs. In cases of sex mismatch of donor/recipient pairs, FISH technique was used. Immune reconstitution was investigated at +1, +3, +6, +12 and +24 months by monitoring of CD2, CD3, CD4, CD8, CD19 and CD20. In addition, CD11 and CD18 markers were studied for individuals with type 1 leukocyte adhesion deficiency (LAD-1).
Outcome and variable definitions
The day of stem cell transplantation was defined as day 0. The first of the 3 consecutive days with an ANC of 0.5 × 10 9 /L or more was defined as the day of neutrophil engraftment. Day of platelet engraftment was defined as the first day of 3 consecutive days in which the platelet count has exceeded 20 × 10 9 /L without platelet transfusion for 7 days. Primary graft failure was defined as failure to maintain absolute neutrophil count 4 0.5 × 10 9 /L for 3 consecutive days after HSCT by day +28 after BM or PBSC or by day +42 after CB grafts. 21 Secondary graft failure was defined as initial engraftment followed by decline of donor cells to less than 5%. 22 Full chimerism and mixed chimerism were described by detection of 495% and 5-95% of donor's hematopoietic stem cells in recipient's BM or peripheral blood, respectively. 23 Mixed chimerism was also further categorized into two groups: low level (5-49%) and high level (50-95%). Acute GvHD and chronic GvHD were graded according to the standard criteria. 24, 25 Overall survival (OS) and disease-free survival (DFS) rates were estimated from the day of transplantation. OS was defined as the time elapsed between day 0 and death from any cause. 26 DFS was defined as the time period between HSCT and recurrence of the primary disease or death from any cause. 26 
Statistical analysis
The primary end points of this prospective study were survival and chimerism (among patients with successful primary engraftment). As no secondary graft failure was observed, chimerism was defined as a dichotomous variable consisting of full and mixed forms. The secondary end points included acute and chronic GvHD. Continuous variables were presented as median and range. Categorical variables were presented as frequency and percentages. Student's t-test and chi-square test were used to compare continuous and categorical variables between mixed and full chimerism groups, respectively. Fischer's exact test was applied when appropriate.
OS and DFS curves were estimated through the Kaplan-Meier method. To assess the impact of variables on OS and DFS, Cox proportional hazards regression was implemented and hazard ratio (HR) with 95% confidence interval (CI) was reported. Proportionality of the included variables was approved by Schoenfeld residuals testing. Estimated P-values were twosided and a significant P-value was one less than 0.05. Data were processed with STATA version 11.2 software (Statacorp, College Station, TX, USA).
RESULTS
Demographic and clinical characteristics
A total of 45 consecutive children with various types of PIDs underwent allogeneic HSCT at our center. Patients' and donors' baseline characteristics and the number of surviving children categorized by each characteristic are outlined in Table 1 . All patients had suffered before from opportunistic and resistant infections and had been hospitalized several times before their admission for HSCT. At the time of transplantation, two children had active fungal pneumonia, six were suffering from active infectious ulcers of considerable size on their limbs and one child had nephrotic syndrome. Five children were under antituberculosis treatment when admitted to transplantation ward due to disseminated BCG-osis caused by vaccination at birth. Fourteen children with primary hemophagocytic lymphohistiocytosis including familial erythrophagocytic lymphohistiocytosis (FEL), Griscelli syndrome and Chediak-Higashi syndrome had experienced at least 1 hemophagocytic lymphohistiocytosis crisis phase before HSCT and 13 of them were in remission while 1 patient was in accelerated hemophagocytic lymphohistiocytosis phase when he underwent transplant procedure.
The most common indications for HSCT were LAD-1 (n = 17, 38%) and Wiskott-Aldrich syndrome (WAS) (n = 7, 16%). Median age at the time of diagnosis and transplantation was 6 months (range: 3-72 months) and 21 months (range: 4-180 months), respectively. Median time from diagnosis to HSCT was 12 months (range: 1-128 months). Duration of admission period ranged between 19 and 157 days (median, 31 days). Donor age ranged between 3 and 74 years (median, 22 years). As shown in Table 1 At the time of the last follow-up, of 41 patients with successful engraftment, 33 (80%) maintained stable full donor chimerism and 8 had stable mixed chimerism (20%). Of these mixed chimerism patients, five had low-level chimerism (⩽49% donor chimerism). None of the patients with mixed chimerism showed symptoms or complications of the underlying immunodeficiency disease during the follow-up period. Table 2A displays the characteristics of patients with low-level chimerism.
All patients who sustained the mixed chimerism status received stem cells from full-match related donors (Fischer's exact test P-value = 0.318). No correlation was detected between chimerism status and type of the underlying PID, stem cell source, age at diagnosis and time between diagnosis and HSCT.
GvHD and other complications Acute GvHD developed in 27 out of 41 patients with primary engraftment (66%). This included 11 patients with grade I-II and 16 (39%) children with grade III-IV acute GvHD, including 10 (24%) with grade IV acute GvHD. Of these, two (7%) had mixed chimerism and the rest (n = 25, 93%) had full chimerism at the time of acute GvHD diagnosis (Fischer's exact test P-value = 0.035), indicating acute GvHD occurrence correlates with full donor chimerism. Variables that showed no significant impact on acute GvHD incidence included patient-donor relationship, source of stem cells, HLA matching status, age at diagnosis, time between diagnosis and HSCT and time to neutrophil recovery. Overall, 11 out of 37 patients alive at day +100 were affected by chronic GvHD (30%). It was limited in seven and extensive in four cases. Chronic GvHD was observed in two children without prior history of acute GvHD, in four with grade I-II and in five with grade III-IV acute GvHD (Fischer's exact test P-value = 0.129). Although chronic GvHD incidence was more common in patients with acute GvHD, the association was not statistically significant (n = 9 vs n = 2, Fischer's exact test P-value = 0.071). Chronic GvHD was not observed in patients with mixed chimerism (Fischer's exact test P-value = 0.071). Patient-donor relationship, source of stem cells, degree of HLA matching, the presence of infection at the time of transplantation and time to neutrophil recovery had no significant influence on chronic GvHD occurrence.
Overall, 23 (51%) patients developed CMV infection. Gancyclovir was started immediately and all except one patient, who expired due to CMV disease, was treated effectively. There was no correlation between chimerism status and CMV infection (Fischer's exact test P-value = 0.494). Positive CMV test did not have any statistically significant association with survival (P = 0.445).
No veno-occlusive disease, hemorrhagic cystitis, severe mucositis and interstitial pneumonitis were reported. In addition, the WAS patient suffering from nephrotic syndrome before HSCT has been proteinuria free since day +70.
OS, DFS and transplant-related mortality
The median follow-up period of all living patients was 49.4 months (range: 18.1-85.5 months). To date, 34 of 45 patients treated by allogeneic RIC-HSCT are alive of whom 31 are disease free with no evidence of the primary disease symptoms and recurrent infection. All surviving patients with successful engraftment demonstrated weight gain appropriate for age after transplantation and have good quality of life. They have satisfactory immune reconstitution and do not require immune replacement therapy. Immune reconstitution 6 and 12 months after transplantation by Abbreviations: BM = bone marrow; CB = cord blood; F = female; HSCT = hematopoietic stem cell transplantation; LAD-I = type 1 leukocyte adhesion deficiency; M = male; WAS = Wiskott-Aldrich syndrome. Abbreviations: BM = bone marrow; CB = cord blood; CHS = Chediak-Higashi syndrome; FEL = familial erythrophagocytic lymphohistiocytosis; GS-type II = Griscelli syndrome type II, HSCT = hematopoietic stem cell transplantation; LAD-1 = type 1 leukocyte adhesion deficiency; PB = peripheral blood; PID = primary immunodeficiency disorder; WAS = Wiskott-Aldrich syndrome. the mean of the absolute numbers of cells is shown in Figure 1 . In general, 100-day post transplantation mortality rate was 17.78% (95% CI: 9.32-34.42%). One-year mortality rate was 22.22% (95% CI: 12.63-37.36%). As shown in Figure 2 , five-year OS was 75.56% (95% CI: 60.22-85.65%) and five-year DFS was 68.89% (95% CI: 53.20-80.25%), regarding the entire cohort. Breakdowns of fiveyear OS by the source of stem cells, donor-patient relationship, degree of HLA matching and type of PID are shown in Figure 3 .
Of the four patients (one female and three males) with primary engraftment failure (Table 2B) , three are alive. One is affected by WAS and two suffer from LAD-1. They are under prophylactic therapy, have been hospitalized several times due to infections and are candidates for second HSCT. The fourth patient who suffered from LAD-1 expired at day +120 due to sepsis.
A total of 11 deaths caused by transplant-related mortality were observed. Causes of death included sepsis (n = 5), grade IV acute GvHD (n = 3) and chronic GvHD (n = 2) and sepsis after primary graft failure (n = 1). Multivariable Cox regression analysis is detailed in Table 4 . Only using BM as the stem cell source had a significant statistical impact on survival (HR = 7.19 95% CI: 1.02-50.69). Although using BM as stem cell source showed higher risk of mortality in multivariable Cox regression, the range of 95% CI was considerably wide indicating an imprecise estimate ( Table 4 ). The limited number of patients might have affected the result of our analysis.
DISCUSSION
PIDs are rare genetic diseases and most of them are lethal in childhood, mainly due to serious infections. Despite allogeneic HSCT being recognized as a curative approach in children suffering from various types of PIDs [27] [28] [29] and in spite of improved techniques a number of issues remain to be answered including the best conditioning regimen and the level of chimerism that would ensure cure. Introduction of RIC has offered many patients ineligible for MAC a chance for cure. Further appreciation of RIC and mixed chimerism in PID patients could be explained by the advantage of a lower number of early and late treatment effects such as infertility and growth retardation in comparison with myeloablative regimen. 30 In addition, partial chimerism has been demonstrated to reverse the disease symptoms in numerous studies. 31 Not only may stable mixed chimerism be sufficient to improve patients' condition, but also in some cases might be associated with improved survival. 32, 33 In this prospective study, we illustrated the results of HSCT using a similar RIC regimen consisting of fludarabine, melphalan and horse ATG in a variety of pediatric PIDs. Our results have demonstrated an acceptable primary engraftment rate (91%), which is comparable to previous published data focusing on children with PIDs undergoing MAC or RIC-HSCT. 28, 33 As shown in Table 2A , of four children with failed primary engraftment, three were affected by LAD-1. Three patients (75%) received graft from umbilical CB and two of them had unrelated donors. Recent studies have stated that umbilical cord transplantation in children could have favorable results in long term because of lower rates of GvHD. 34 However, umbilical cord transplantation is also associated with late engraftment related to low total nucleated cell dose, with increased risk of graft failure. 35, 36 It should be noted that children with primary engraftment failures who had received CB transplantation had several unfavorable characteristics including non-full match status, unrelated donors and significant long period of time between diagnosis and HSCT.
Considering the small number of failed primary engraftments, accurate analysis of factors involved is challenging. Type of underlying PID, stem cell source, the presence of infection at the time of HSCT and donor-patient relationship did not show significant association with chimerism status in successful engraftments. Although, we have previously reported successful HSCT using the same RIC protocol in patients with LAD-1 23 and breakdown of diagnostic entities into LAD and non-LAD cases did not produce statistically significant results considering primary engraftment failure, we speculate that hyperactivity of myeloid macrophage lineage in these patients, particularly due to chronic stimulation of BM caused by persisting bacterial infection, 37 could have a role in unfavorable engraftment results. 38 Further clinical and preclinical investigations are warranted.
Numerous studies have shown improved survival and less morbidity with RIC compared with conventional conditioning. 30, 39 Triplet et al. 40 examined 52 pediatric patients with PIDs and displayed a 6-year OS of 72 ± 8% for the entire cohort and indicated better event-free survival with RIC regimen that is in accord with our 5-year OS of 75.56% (95% CI: 60.22-85.65%).The 2012 report of center for international blood and marrow transplant research 41 showed that +100-day mortality after HLAidentical sibling and unrelated donor transplants in immunodeficiencies was about 18 and 16%, respectively. Our data indicated a similar +100-day mortality figure (17.7%). Rao et al. 8 have reported their results of 19 children suffering from PID undergoing HSCT from 1994 to 1999 using MAC regimen consisted of busulphan (16 mg/kg) and cyclophosphamide (200 mg/kg). They achieved a 1-year OS of 57.89%. 8 As most transplant procedures involving pediatric patients with PID and MAC regimen took place in earlier years, the advances in supporting care might have further contributed to the higher rate of survival in these patients. 42 There are multiple RIC protocols used in medical centers all around the globe. As PID is a rare disease, comparison of diverse regimens is quite challenging, if not impossible. Thus, the optimal RIC protocol specified for different types of PIDs remains to be determined. Chiesa and Veys 13 have recently conducted a review discussing different RIC regimens used in PID-HSCTs and have suggested the combination of fludarabine and melphalan as the favored regimen in children older than 1 year, due to its association with less long-term morbidities. Rao et al. 8 reported the results of transplants from unrelated donors in 113 patients with PIDs using RIC and MAC regimens. Alemtuzumab, fludarabine and melphalan were used as the conditioning regimen in RIC group. This study demonstrated a reduced overall mortality in RIC group.
Although previous studies have found that the presence of active infection is related to poor survival rate, 43 we did not observe a statistically significant association between the presence of active infection at the time of transplantation and mortality (Table 3) . This finding could demonstrate that our RIC regimen might be associated with favorable outcomes in children with PIDs, particularly those who are suffering from infections.
Although in non-malignant disorders mixed chimerism might be the favorable result due to decreased risk of GvHD and toxicity and improved survival, there are great concerns about increased chance of graft rejection. [44] [45] [46] Sufficiency of mixed chimerism for resolving PID symptoms has also been extensively discussed. Despite some studies showing lower chance of complete immune reconstitution in mixed chimerism states, 47 various studies investigating a range of PIDs found stable mixed chimerism state after RIC-HSCT to be capable of overcoming manifestations of the primary disease. 8, 10, 23, 48 In our study, although mixed chimerism occurred in eight patients (20%) and five of them had ⩽ 49% of donor cells (Table 2B) , no secondary graft failure was observed with a median follow-up of 35.5 months. All of them are currently disease free with no manifestation of infection and mixed chimerism was sufficient to correct the underlying disease during our follow-up period.
We observed a rather high rate of acute GvHD in our study population. Notably, all children who developed grade III or IV acute GvHD had full chimerism status (P = 0.017). Patients with mixed chimerism status had a significantly lower affinity for development of GvHD. Of the eight children with mixed chimerism, two had acute GvHD, both grade I/II. The association between higher incidence of grade II-IV acute GVHD and full chimerism has previously been discussed. 49 Interestingly, in mixed chimerism status no chronic GvHD was observed, which could have further improved the chance of survival. In addition, there was no death in the mixed chimerism cohort. Nevertheless, the small number of our patients restricts further analysis and additional investigations are warranted to consider mixed chimerism status a favorable feature.
There is a controversy surrounding application of PBSCs considering reports of higher rates of GvHD in contrast to enhanced chimerism status and subsequent similar OS rates compared with BM-HSCT. 13, 18 Our data showed using BM as stem cell source was related to an increased probability of mortality in comparison with using PBSCs (HR = 7.19 (95% CI: 1.02-50.68)). However, the CI is wide stating that the sample size is small and the point estimate is imprecise. Nevertheless, PBSC-HSCT was associated with improved survival in our study.
CONCLUSION
Fludarabine, melphalan and horse ATG is a well-tolerated RIC regimen that leads to favorable OS in children with a variety of PIDs. Application of this particular regimen could be practical in developing countries, markedly in districts where due to late referral, patients are usually associated with infection and BCG vaccination is mandatory at birth. However, receiving grafts from mismatched and unrelated donors had a negative impact on survival. Because of the rarity of PIDs, a large multicenter prospective study is warranted to determine the optimal stem cell source and RIC regimen for improvement of HSCT results in PID patients.
